Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.5% – Here’s What Happened

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was down 1.5% during mid-day trading on Tuesday . The stock traded as low as $6.65 and last traded at $6.66. Approximately 494,945 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 5,738,237 shares. The stock had previously closed at $6.76.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on RXRX shares. KeyCorp lowered their price target on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Jefferies Financial Group lowered their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Needham & Company LLC reduced their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Finally, Leerink Partners decreased their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Stock Performance

The company has a fifty day moving average of $6.73 and a 200 day moving average of $7.74. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The stock has a market cap of $1.50 billion, a P/E ratio of -3.96 and a beta of 0.80.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The business had revenue of $14.42 million during the quarter, compared to the consensus estimate of $11.96 million. During the same quarter last year, the firm posted ($0.38) earnings per share. Recursion Pharmaceuticals’s revenue was up 30.9% compared to the same quarter last year. On average, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total value of $76,351.49. Following the transaction, the director now owns 7,089,007 shares in the company, valued at approximately $47,283,676.69. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, October 8th. The shares were sold at an average price of $6.32, for a total value of $94,800.00. Following the completion of the transaction, the chief financial officer now directly owns 1,426,506 shares in the company, valued at $9,015,517.92. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total transaction of $76,351.49. Following the sale, the director now directly owns 7,089,007 shares in the company, valued at approximately $47,283,676.69. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 195,682 shares of company stock worth $1,284,153 in the last ninety days. 15.75% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC acquired a new position in shares of Recursion Pharmaceuticals in the 3rd quarter valued at about $25,000. Benjamin F. Edwards & Company Inc. purchased a new stake in Recursion Pharmaceuticals in the 1st quarter worth approximately $26,000. GAMMA Investing LLC boosted its stake in shares of Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after buying an additional 6,036 shares during the period. Amalgamated Bank grew its holdings in shares of Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after acquiring an additional 2,459 shares in the last quarter. Finally, San Luis Wealth Advisors LLC purchased a new stake in shares of Recursion Pharmaceuticals during the third quarter worth $69,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.